Showing 7171-7180 of 9550 results for "".
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- FDA OKs Coolsculpting for Upper Arm Fat Reductionhttps://practicaldermatology.com/news/fda-oks-coolsculpting-for-upper-arm-fat-reduction/2458300/ZELTIQ® Aesthetics, Inc.’s CoolSculpting is now US Food and Drug Administration (FDA)-cleared for fat reduction in the upper arms.
- Dr. David Norris Named New ASA Presidenthttps://practicaldermatology.com/news/dr-david-norris-named-new-asa-president/2458304/David Norris, MD, Chairman of the Department of Dermatology at the University of Colorado School of Medicine, is the new President of American Skin Association (ASA). Dr. Norris has been a part of ASA since 1997, serv
- Congratulations: American Skin Association Announces 2017 Research Scholar Awards and Research Grantshttps://practicaldermatology.com/news/congratulations-american-skin-association-announces-2017-research-scholar-awards-and-research-grants/2458307/And the winners are … The American Skin Association (ASA) research scholar awards and research grants are: ASA Carson Research Sc
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro
- ISDIN: Broad Spectrum Sun Protection Cream with DNA Repair Beneficial Post AK Treatmenthttps://practicaldermatology.com/news/isdin-broad-spectrum-sun-protection-cream-with-dna-repair-beneficial-post-ak-treatment/2458319/ISDIN has reported promising results of a 9-month, randomized, investigator-blinded parallel-group study in a poster presentation at the Winter Clinical Conference. The study was designed to evaluate clinical effects of a high SPF film-forming emulsion co
- Scarless Wound Healing Breakthrough: Researchers Turn Myofibroblasts in Wounds into Adipocyteshttps://practicaldermatology.com/news/scarless-wound-healing-breakthrough-researchers-turn-myofibroblasts-in-wounds-into-adipocytes/2458326/Scientists can now transform myofibroblasts found in wounds into adipocytes, paving the way toward scarless healing. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the P
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad